Developing a personalized biological therapy for the treatment of pancreatic and ovarian cancer
| Reference number | |
| Coordinator | Icellate Medical AB - ICELLATE MEDICAL AB, Solna |
| Funding from Vinnova | SEK 5 000 000 |
| Project duration | June 2020 - July 2023 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The aim of this project was to develop a cell-bound liquid biopsy-based diagnostic test on the CellMate® oncological in vitro companion diagnostic platform to predict treatment response to treatment target L1CAM, to accompany Antibody Drug Conjugate (ADC) ElMab as an effective diagnostic tool for patient selection (treatment response prediction) and for continuous patient monitoring of disease regression, progression or recurrence using blood samples.
Expected long term effects
The project has developed a new immunotherapy medicinal product candidate for treatment of treatment target L1CAM expressing cancers and two liquid-biopsy based and an immune-histochemistry companion diagnostic assay for treatment stratification and monitoring. The analytical validation of the cellular liquid biopsy test has been performed in pancreas, colon, rectal, breast and ovarian cancer patients. The new medicinal product candidate ElMab and the companion diagnostic tests are ready to be co-developed in phase 1 clinical trials.
Approach and implementation
The ELEVATE project has been a collaboration between Elthera AG (Switzerland), Targos Molecular Pathology GmbH (Germany), Institute for Experimental Cancer Research (Germany) and iCellate Medical AB (Sweden). The project partners have had regular project meetings and tight communication to fulfil project objectives. The results are being summarised, IP to be protected and results to be disseminated at scientific conferences and peer reviewed journals. The project was successful. Discussions are ongoing in relation to the planed phase 1 studies.